Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines

Everolimus (Eve) is an FDA approved drug that inhibits mammalian target of rapamycin (mTOR). It is employed in breast cancer treatment even if its responsiveness is controversial. In an attempt to increase Eve effectiveness, we have developed a novel Eve nanoformulation exploiting H-ferritin nanocag...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics
Main Authors: Bonizzi, Arianna, Truffi, Marta, Sevieri, Marta, Allevi, Raffaele, Sitia, Leopoldo, Ottria, Roberta, Sorrentino, Luca, Sottani, Cristina, Negri, Sara, Grignani, Elena, Mazzucchelli, Serena, Corsi, Fabio
Format: Artigo
Language:Inglês
Published: MDPI 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6723888/
https://ncbi.nlm.nih.gov/pubmed/31382388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics11080384
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items